Patents Examined by Fred H Reynolds
  • Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
    Patent number: 11104713
    Abstract: Described herein are modified integrin ? and/or ? headpiece polypeptides, and crystallizable integrin polypeptide dimers comprising a modified integrin ? and/or ? headpiece polypeptide and a disulfide bond linking the two integrin headpiece polypeptide subunits. Methods for using the modified integrin ? and/or ? headpiece polypeptides and the integrin polypeptide dimers are also provided herein. For example, methods for characterizing integrin-ligand interaction and identifying integrin ligands are also provided herein. In some embodiments, the identified integrin ligands can be used as inhibitors of integrins.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: August 31, 2021
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Timothy Alan Springer, Xianchi Dong, Chafen Lu
  • Synthetic binder of breast cancer stem cells
    Patent number: 11091516
    Abstract: The present disclosure provides a for peptoid compounds that bind selective to cancer stem cells (CSCs), particularly those associated with breast cancer. Conjugates of the peptoids to detactable labels and therapeutic agent are contemplated as are methods of diagnosing and treating breast cancer.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: August 17, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jiyong Lee, Luxi Chen, Chao Long, Zhenpeng Qin, Jonghae Youn, Peiyuan Kang
  • Peptide pharmaceuticals for insulin resistance
    Patent number: 11065304
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 20, 2021
    Assignee: Mederis Diabetes, LLC
    Inventor: John J. Nestor
  • Antigen delivery vectors and constructs
    Patent number: 11066353
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 20, 2021
    Assignee: Altimmune UK Ltd
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand V. Georges, Philip J. Sizer
  • Gene expression inhibitors
    Patent number: 11034726
    Abstract: The present invention relates to a peptide comprising or consisting of an amino acid sequence according to formula (I) X1-X2-X3-X4-X5-(A)m-X6-X7-(X8)n-C (I), wherein X1 is C or S, X2 is L or A, X3 is A, V or L, X4 is F or Y, X5 is Y or F, X6 is C or R, X7 is F or L, X8 is W or A and m and n are independently 0 or 1 or a variant thereof.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 15, 2021
    Assignee: PIVARIS BIOSCIENCE GMBH
    Inventor: Hanna Harant
  • Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH
    Patent number: 11034724
    Abstract: Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: June 15, 2021
    Assignee: Stealth BioTherapeutics Corp.
    Inventor: Scott M. Duncan
  • Capping of unprotected amino groups during peptide synthesis
    Patent number: 11028123
    Abstract: The present invention relates to a method for the synthesis of a polypeptide comprising a pre-determined amino acid sequence. The method according to the invention comprises coupling cycles of coupling an N-terminally protected amino acid building block C-terminally at an unprotected N-terminal amino group of an amino acid chain, wherein at least one coupling cycle comprises a coupling step (a), a capping step (b), and a de-protecting step (c).
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: June 8, 2021
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Bernd Henkel, Tobias Metzenthin, Manfred Gerken, Wolfgang Fiedler
  • Therapeutically active compounds and their methods of use
    Patent number: 11021515
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: June 1, 2021
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof
    Patent number: 10975132
    Abstract: Provided are an improved cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof. Suppressor of cytokine signaling-3 (SOCS3) is an endogenous protein inhibitor of JAK/STAT pathway, and an aberrant expression of SOCS3 protein was observed in human solid tumors including gastric, colorectal and breast cancer, and glioblastoma. The iCP-SOCS3 recombinant protein provided herein may be used as protein-based anti-lung cancer agent by utilizing the platform technology for macromolecule intracellular transduction.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: April 13, 2021
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof
    Patent number: 10961292
    Abstract: Provided are an improved cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof. Suppressor of cytokine signaling-3 (SOCS3) is an endogenous protein inhibitor of JAK/STAT pathway, and an aberrant expression of SOCS3 protein was observed in human solid tumors including gastric, colorectal and breast cancer, and glioblastoma. Thus, the iCP-SOCS3 recombinant protein may be used as protein-based anti-solid tumor agent by utilizing the platform technology for macromolecule intracellular transduction.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: March 30, 2021
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Amino acids bearing a norbornene moiety
    Patent number: 10954537
    Abstract: The invention relates to a novel amino acid having a norbornene group and polypeptide comprising the novel amino acid compounds. The invention also relates to a method of producing polypeptides comprising a norbornene group and to the use of said polypeptides.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 23, 2021
    Assignee: VALANX BIOTECH GMBH
    Inventor: Michael Lukesch
  • Glyco-modified atrial natriuretic peptide
    Patent number: 10947289
    Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: March 16, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Mitsuhiro Iwamoto, Takahiro Yamaguchi, Yutaka Mori, Keiji Saito, Takeshi Honda, Takahiro Nagayama
  • Use of a compound, pharmaceutical composition, and therapeutic method for the treatment or prevention of convulsions
    Patent number: 10933113
    Abstract: The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: the use of a peptide compound for preparing an anticonvulsant pharmaceutical composition; and a therapeutic method. The peptide compound of the claimed pharmaceutical composition binds to and/or modulates the activity of cannabinoid receptors (CB), particularly CB1 and/or CB2, and has proven to be extremely useful as an anticonvulsant. In one embodiment, the claimed pharmaceutical composition provides excellent anticonvulsant results when administered orally to a mammal, and, in addition to other advantages and technical effects, does not entail the drawbacks arising from the use of cannabinoid substances such as cannabidiol, and provides a stronger therapeutic effect in smaller dosages and with fewer side effects.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: March 2, 2021
    Assignee: PROTEIMAX BIOTECNOLOGIA LTD.
    Inventors: Ricardo Amaral Remer, Andrea Sterman Heimann
  • Peptidyl ketoamides as inhibitors of rhomboid proteases
    Patent number: 10927146
    Abstract: Compounds useful for the treatment of malaria, cancer, Parkinson's disease, diabetes, and bacterial infection.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 23, 2021
    Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.
    Inventors: Kvido Strisovsky, Pavel Majer, Stanco Stancev, Anezka Ticha
  • Use of antimicrobial peptides for treatment of cancer
    Patent number: 10918692
    Abstract: Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: February 16, 2021
    Assignee: HUNAN UNIVERSITY OF SCIENCE AND ENGINEERING
    Inventors: Xiaofang Luo, Zuodong Qin, Fulin He, Xiaoping Ouyang, Zhizhang Li, Changjian Li, Qianrui Peng, Zhesheng Chen
  • Topical cyclosporine-containing formulations and uses thereof
    Patent number: 10918694
    Abstract: Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: February 16, 2021
    Assignee: SUN PHARMA GLOBAL FZE
    Inventors: Sidney L. Weiss, Ashim K. Mitra, Eugene J. McNally
  • Degradable thiol-ene polymers and methods of making thereof
    Patent number: 10912837
    Abstract: Provided are methods for linking polypeptides (including peptides and proteins) to other moieties using radical imitated thiol-ene chemistries, for example, modifying a polypeptide by introducing reactive thiol groups and reacting the thiol groups with olefin-containing reagents or alkyne-containing reagents under conditions that support radical thiol-ene or thiol-yne reactions. The reactive thiol groups have greater activity for radical thiol-ene reactions that a cysteine thiol group, including thiol groups that are separated from the peptide backbone by at least two carbon atoms, for example, the thiol group of a homocysteine residue. Also provided are compositions and biomaterials containing the linked polypeptides, for example, peptide and protein conjugates, and thiol-ene based biocompatible hydrogel polymers, and their uses in the medical field.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: February 9, 2021
    Assignee: MOSAIC BIOSCIENCES, INC.
    Inventors: Alexei V. Kazantsev, Peter D. Mariner, Martin Stanton
  • Use of antimicobial peptides for treatment of infection
    Patent number: 10898541
    Abstract: Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: January 26, 2021
    Assignee: HUNAN UNIVERSITY OF SCIENCE AND ENGINEERING
    Inventors: Xiaofang Luo, Zuodong Qin, Fulin He, Xiaoping Ouyang, Zhizhang Li, Changjian Li, Qianrui Peng, Zhesheng Chen
  • Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
    Patent number: 10875900
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: December 29, 2020
    Assignee: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • De novo design of protein switches
    Patent number: 10851135
    Abstract: Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain, components of such protein switches, and their use.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: December 1, 2020
    Assignee: University of Washington
    Inventors: Robert A. Langan, Scott Boyken, David Baker, Walter Novak, Marc Joseph Lajoie, Alfredo Quijano Rubio